RP 70676 是一種有效的 <b>ACAT</b> 抑制劑,能夠抑制對大鼠和兔子中的 ACAT 活性,<b>IC<sub>50</sub></b> 值分別為 25 和 44 nM。<BR><a href="https://www.medchemexpress.cn/PQR620.html">PQR620</a>產品描述:PRQ620 is a highly potent and selective mTORC1/2 inhibitor, shows anti-tumor effects in vitro and in vivo. target: mTORC1/2IC 50: 0.2 μM and 0.1 μM.In vitro: In A2058 melanoma cells PQR620 demonstrated inhibition of protein kinase B (pSer473) and ribosomal protein S6 (pSer235/236) phosphorylation with IC50values of 0.2 μM and 0.1 μM, respectively. PQR620 demonstrated its potency to prevent cancer cell growth in an NTRC 44 cancer cell line panel, resulting in a 10log(IC50) of 2.86 (nM), induced a >1000-fold selectivity towards mTOR over PI3Kα in enzymatic binding assays. showed excellent selectivity over a wide panel of kinases, as well as excellent selectivity versus unrelated receptor enzymes and ion channels. [1]In vivo: PQR620 result in good oral bioavailability and excellent brain penetration. [1]<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網點遍及全球20多個國家地區(qū)。MCE經過多年努力已成為全球生物活性小分子領域的一流供應商, 產品涵蓋癌癥、神經科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產品都進行嚴格的LCMS和NMR檢驗,其產品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數千種產品在上海有充足備貨,24-48小時內送達客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產品提供免費試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。</span><br><br>產品鏈接:<a href="http://www.medchemexpress.cn/PQR620.html">www.medchemexpress.cn/PQR620.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt="">Purity:98%<BR>MWt:416.5816<BR>Formula:C25H28N4S<BR>SMILES:CC1=CC(C)=NN1CCCCCSC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N2<BR>Pathway:Others; <BR>Mechanisms:Others; <BR>Research Area:metabolic Disease<BR>電話: 021-58955995<BR>網址: www.MedChemExpress.cn <BR>地址: 上海市浦東新區(qū)蔡倫路720號2號樓3層 |
RP 70676前沿研究進展
發(fā)布日期:2017-11-13 瀏覽次數:0
核心提示:RP 70676 是一種有效的 bACAT/b 抑制劑,能夠抑制對大鼠和兔子中的 ACAT 活性,bICsub50/sub/b 值分別為 25 和 44 nM。BRa href=
- 下一篇:暫無
- 上一篇:Acetylazide前沿研究進展
行業(yè)動態(tài)
更多...
- RP 70676前沿研究進展 11-13
- Acetylazide前沿研究進展 11-13
- Pratosartan前沿研究進展 11-13
- Bencianol前沿研究進展 11-13
- MHP前沿研究進展 11-13
- GSK1059865前沿研究進展 11-13
- IT1t前沿研究進展 11-13
- Darbufelone (mesylate)前 11-13
- sulfo-SPDB-DM4前沿研究進 11-13
- SGD-1882前沿研究進展 11-13